Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

References for PMC Articles for PubMed (Select 17322365)

1.

Modulation of Doxorubicin sensitivity and level of p-glycoprotein expression in human colon-carcinoma cells by ectopic and orthotopic environments in nude-mice.

Wilmanns C, Fan D, Obrian C, Radinsky R, Bucana C, Tsan R, Fidler I.

Int J Oncol. 1993 Sep;3(3):413-22.

PMID:
21573380
2.

Regulation of cardiac hypertrophy by intracellular signalling pathways.

Heineke J, Molkentin JD.

Nat Rev Mol Cell Biol. 2006 Aug;7(8):589-600. Review.

PMID:
16936699
3.

The mighty mouse: genetically engineered mouse models in cancer drug development.

Sharpless NE, Depinho RA.

Nat Rev Drug Discov. 2006 Sep;5(9):741-54. Epub 2006 Aug 18. Review.

PMID:
16915232
4.

Mouse models in oncogenesis and cancer therapy.

Céspedes MV, Casanova I, Parreño M, Mangues R.

Clin Transl Oncol. 2006 May;8(5):318-29. Review.

PMID:
16760006
5.

Barriers to efficient development of cancer therapeutics.

Schein PS, Scheffler B.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3243-8. Review. No abstract available.

6.

Genetically engineered models have advantages over xenografts for preclinical studies.

Becher OJ, Holland EC.

Cancer Res. 2006 Apr 1;66(7):3355-8, discussion 3358-9. Erratum in: Cancer Res. 2006 May 15;66(10):5526.

7.

Contributions of human tumor xenografts to anticancer drug development.

Sausville EA, Burger AM.

Cancer Res. 2006 Apr 1;66(7):3351-4, discussion 3354. Review.

8.

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.

Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV.

Blood. 2006 Jul 15;108(2):618-21. Epub 2006 Mar 28.

9.

Cancer statistics, 2006.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ.

CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30.

PMID:
16514137
10.

Experimental models to study development and function of the human immune system in vivo.

Legrand N, Weijer K, Spits H.

J Immunol. 2006 Feb 15;176(4):2053-8. Review.

11.

Cytochrome P450 and xenobiotic receptor humanized mice.

Gonzalez FJ, Yu AM.

Annu Rev Pharmacol Toxicol. 2006;46:41-64. Review.

12.

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.

Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, Coutant F, Métivier D, Pichard E, Aucouturier P, Pierron G, Garrido C, Zitvogel L, Kroemer G.

J Exp Med. 2005 Dec 19;202(12):1691-701.

13.

Humanized mice: are we there yet?

Macchiarini F, Manz MG, Palucka AK, Shultz LD.

J Exp Med. 2005 Nov 21;202(10):1307-11.

15.

Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo.

Thomsen M, Yacoub-Youssef H, Marcheix B.

Tissue Antigens. 2005 Aug;66(2):73-82. Review.

PMID:
16029426
16.

50 years of preclinical anticancer drug screening: empirical to target-driven approaches.

Suggitt M, Bibby MC.

Clin Cancer Res. 2005 Feb 1;11(3):971-81. Review.

17.

Modeling variation in tumors in vivo.

Stringer JR, Larson JS, Fischer JM, Medvedovic M, Hersh MN, Boivin GP, Stringer SL.

Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2408-13. Epub 2005 Feb 3.

18.

Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.

Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P.

Mol Cancer Res. 2004 Nov;2(11):632-42.

19.

Nutritional-pharmacological combinations--a novel approach to reducing colon cancer incidence.

Schwartz B, Birk Y, Raz A, Madar Z.

Eur J Nutr. 2004 Aug;43(4):221-9. Epub 2004 Jan 6.

PMID:
15309441
20.

Trials, tribulations, and trends in tumor modeling in mice.

Schuh JC.

Toxicol Pathol. 2004 Mar-Apr;32 Suppl 1:53-66. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk